A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral TP-271 in Healthy Adult Subjects, Including 1 Cross-over Arm
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
At a glance
- Drugs TP 271 (Primary)
- Indications Bacterial infections
- Focus Adverse reactions
- Sponsors Tetraphase Pharmaceuticals
- 14 Feb 2018 Planned End Date changed from 1 Oct 2017 to 1 May 2018.
- 06 Sep 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 20 Jan 2017 New trial record